Janux Therapeutics, Inc. (JANX) Free cash flow 2020–2025
Janux Therapeutics, Inc. (JANX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$83.3MFY2025 · since FY2020: -$4.4M → -$83.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$83.3M | -88.5% |
| FY2024 | -$44.2M | +15.7% |
| FY2023 | -$52.4M | -6.2% |
| FY2022 | -$49.4M | -167.5% |
| FY2021 | -$18.5M | -322.5% |
| FY2020 | -$4.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More JANX financial trends
JANX RevenueJANX Net incomeJANX Net marginJANX Gross profitJANX Gross marginJANX Operating incomeJANX Operating marginJANX Operating cash flowJANX Capital expendituresJANX Return on equityJANX Stock buybacksJANX Dividends paidJANX Total assetsJANX Total liabilitiesJANX Shareholders’ equityJANX overview →